AbbVie Inc - Company Profile
Powered by
All the data and insights you need on AbbVie Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date AbbVie Inc Strategy Report
- Understand AbbVie Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreView up-to-date information on AbbVie Inc patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
HRP20171966T4 | Grant | STABILIZED NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS | A61K2800/522; A61K2800/84; A61K38/164; A61K38/48; A61K38/4893; A61K47/02; A61K47/10; A61K47/18; A61K47/183; A61K47/20; A61K47/22; A61K47/26; A61K47/34; A61K8/60; A61K8/66; A61K9/0019; A61K9/08; A61K9/19; A61P13/00; A61P17/00; A61P21/00; A61P25/24; A61P29/00; A61P9/06; A61Q19/00; Y02A50/30 | September 16, 2022 |
HRP20190762T1 | Grant | USE OF PILOCARPINE HYDROCHLORIDE FOR THE TREATMENT OF PRESBYOPIA | A61K31/4178; A61K47/02; A61K47/12; A61K47/186; A61K9/0048; A61P27/02; A61P27/10 | September 16, 2022 |
WO2022132997A9 | Search Report | BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS | C07D471/04; C07D487/04; C07D519/00 | September 15, 2022 |
EP4054585A1 | Application | DOSIERUNGSSCHEMATA ZUR VERWENDUNG BEIM BEHANDELN VON MYELOFIBROSE UND MPN-BEZOGENEN STÖRUNGEN MIT NAVITOCLAX | A61K2300/00; A61K31/519; A61K31/52; A61K31/5377; A61K31/635; A61P35/00; A61P35/02 | September 14, 2022 |
US20220281882A1 | Application | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | A61K31/4985; A61K47/12; A61K47/38; A61K9/0053; C07B2200/13; C07D487/14 | September 08, 2022 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer